COVID-19: Pivoting to recovery

As the COVID-19 pandemic continues and the vaccine rollout proceeds at varying paces across the globe, organisations find themselves in different and sometimes multiple stages of the crisis management lifecycle. Using Control Risks’ Readiness, Response and Recovery methodology, we are helping clients navigate their way through the crisis by shaping responses that target rapid commercial recovery and factor in longer-term scenarios. We provide critical insights and advice on how to manage fast-moving information cycles and adapt your existing crisis recovery measures to new developments. Remaining flexible, agile, forward-thinking and empathetic are all essential for a successful outcome.

In the race to get ahead of the next major crisis, data is king

The COVID-19 pandemic showed that companies need effective data analysis and monitoring to better plan for and manage crises and disruptions to business continuity. Read our three key points.

Response

Hurricane preparedness in the time of COVID-19

Hurricane forecasts and overall climate related trends indicate that we should expect another “above-normal” season of potentially devastating storms in the Americas. When coupled with the fact that many employees are still working remotely due to the pandemic, an intense hurricane season is an especially challenging crisis to plan for and manage.

Recovery

Pandemic will test Tokyo 2020 to the finish line – whenever that may be

The postponed summer event is currently scheduled to proceed. But doubts will likely linger to the last minute about whether it really is, and indeed, whether it should. We take a look at the risks to manage for all those involved in the event.

Recovery

COVID-19 vaccine diplomacy – from nationalism to friendship

Vaccine rollouts have begun quickly in some countries while others wait. We examine the divergent impacts on diplomatic relations between states prioritising domestic vaccination and others sharing their doses overseas.

Recovery

Navigating third-party risks in pharma and life sciences

Compliance leads at pharmaceutical and life sciences companies have one of the least navigable jobs in our field. The complexity and uncertainty surrounding the COVID-19 pandemic has presented an array of operational issues with third-party compliance.